Document:

​
Exhibit 10.1
​
RESIGNATION AND SEPARATION AGREEMENT
​
THE UNDERSIGNED PARTIES:
​
uniQure biopharma B.V., a company with limited liability, having its registered office and principal place of business in Amsterdam duly represented in this matter by J.L. Burggraaf hereinafter referred to as “Employer”,
​
and
​
Dr. Sander J. van Deventer, hereinafter referred to as “Employee”,
Hereinafter jointly referred to as “Parties”;
​
WHEREAS:
​
The Employee has been employed by the Employer since 7 August 2017, most recently on the basis of an open-end employment contract dated 20 August 2019 (the “Employment Contract”) in the position of Executive Vice President, Research and Product Development. The Employee’s most recently earned salary is €29,435 gross per month, including holiday allowance and other emoluments;
​
a)           The Employee has informed the Employer about his intention to resign immediately in order to pursue other opportunities;
​
b)           The Employee has been on a leave of absence effective on or about July 27, 2020;
​
c)           The Employer desires to retain Employee for an additional period to allow for the orderly transition of the Employee’s duties and of related functions of the organization for which Employee currently has responsibility; and
​
d)           The Employee and Employer have agreed to the arrangements provided below to facilitate an orderly transition and to terminate the Employment Contract, which arrangements they wish to lay down as follows in this agreement (hereinafter referred to as the “Agreement”), which they intend to constitute their entire settlement;
​
DECLARE THAT THEY HAVE AGREED AS FOLLOWS:
​
1.        The Effective Date of this Agreement is August 25, 2020.
​
2.        The Employment Contract will end due to the resignation of the Employee on September 14, 2020 (hereinafter referred to as the “Termination Date”) without requiring any further legal act by either Party.
​
3.        The Employer will pay the Employee a gross employment termination payment equal to the Severance Pay as defined in Sections 2.4.1  and 2.4.3 of the Employment Contract (i.e., € 588.700) to compensate for the Employee’s loss of wages and/or to supplement benefits paid pursuant to social security legislation (hereinafter referred to as the “Employment Termination Payment”).
​

​
4.        The Employer will transfer the Employment Termination Payment to the Employee’s bank account as currently known to the Employer no later than four weeks after the Termination Date.
​
5.        As of the Effective Date, the Employee will not be performing his role as, and will not have the title of, Executive Vice President, Research and Product Development, and instead agrees to have the title and role of, Scientific Advisor during the organizational transition prior to the Termination Date.
​
6.        Until the Termination Date, the Employee will receive the usual gross monthly salary of €29.435,00. All other terms of employment will remain in full force and effect until the Termination Date unless the Parties stipulate otherwise in this Agreement.
​
7.        At the Employee’s written request, the Employment Contract may be terminated before the Termination Date (hereinafter referred to as the “Earlier Termination Date”) for purposes of pursuing a bone fide employment opportunity. Upon such written request, the Employee will not be obliged to observe the notice period, and all references to “Termination Date” in this Agreement will be construed as reading “Earlier Termination Date”.
​
8.        The Employer, in its sole discretion subject to applicable law, may choose to put the Employee on garden leave at any time on or after the Effective Date and prior to the Termination Date. Garden leave will be considered equal to continuation of employment at the current Pro-rata Base Salary, and the Employee will continue his working duties as a Scientific Advisor to the Employer.
​
9.        By signing this Agreement and as of the Effective Date, the Employee resigns his position and steps down as director of the Employer, the Employer’s affiliates and all other companies where he was appointed as a director as part of his Employment Contract with the Employer.  As soon as possible thereafter and with immediate effect, the Employee’s entry as director of the Employer and the Employer’s affiliates will be removed from the records of the Commercial Register of the Chamber of Commerce. The Employee will cooperate with said deregistration.
​
10.      The Employer will advise the competent body to discharge the Employee from liability for the policies pursued and management conducted by the Employee until that time at the next meeting. The competent body will only be able to adopt that resolution if it is established that no facts or circumstances exist that render it impossible to grant the Employee discharge from liability. At the time of signing this Agreement, each of the Employer and the Employee is not aware of any facts and/or circumstances that render it impossible to grant the Employee discharge from liability. Upon request, the Employee will be given a copy of the relevant minutes.
​
11.      The equity agreements concluded between Employer and Employee pursuant to the uniQure N.V. 2014 Share Incentive Plan as amended (hereinafter referred to as the “Equity Plan”) will 
​

remain in full force and effect per their terms and are not altered by the terms of this Agreement, except as expressly provided in this paragraph, namely:
​
11.1     Pursuant to this Agreement, all grants of equity will continue to vest until the Termination Date, at which time all such grants of equity shall cease to vest (excepting the grants of Performance Share Units (hereinafter referred to as “PSUs”) addressed in item (iii) below);
​
11.2     Any unvested shares of the three grants of options to purchase ordinary shares of uniQure N.V. dated on or about 20 September 2017, 26 January 2018, and 26 January 2019 respectively will accelerate and be fully vested as of the Termination Date; and
​
11.3     The PSUs that have been earned as of the Termination Date (i.e., the PSUs dated on or about 26 January 2018 and 26 January 2019 respectively), will vest according to their terms (i.e., three years following the grant date subject to the terms and conditions of the respective equity grants).
​
12.      This Agreement, including, without limitation, all provisions related to grants of equity pursuant the Equity Plan, is subject to the approval of the Board of Directors of uniQure N.V. (the “Board”).  This Agreement shall be void if not approved by the Board within thirty (30) days of the Effective Date unless another date is mutually agreed to in writing by the Parties.
​
13.      Within four weeks of the Termination Date the Employer will draw up a regular final settlement.  Holiday and other leave entitlement will be deemed to have been taken at the Termination Date. The Employee hereby expressly waives any compensation for holiday and other leave entitlement that he has accrued but not taken.  Employee shall be allowed to take any remaining holiday and other leave entitlement during the period from the Effective Date to the Termination date, and Employee shall coordinate such leave with Employer’s human resources department.  Periods during which the employee is consuming his holiday and other leave shall not be considered garden leave.
​
14.      Apart from the foregoing, the Employer will not owe the Employee any other compensation, in any form or for any reason whatsoever, irrespective of the provisions of the Employment Contract and/or any applicable collective bargaining agreement (“CAO”), unless this Agreement expressly provides otherwise. The Employee is no longer entitled to any amounts in bonuses, commissions, profit-sharing and/or variable remuneration (in any form or for any year whatsoever).
​
15.      The Employee acknowledges that he is not entitled to any transitional compensation within the meaning of Section 673 of Book 7 of the Dutch Civil Code. If and in so far as necessary, the Parties agree that any transitional compensation is included in the Employment Termination Payment.
​
16.      RESERVED.
​
17.      The Employee will return all items that are in his possession by virtue of his Employment Contract, including any computers, computer equipment, mobile telephone, keys, and cards.
​

Pursuant to Clause 11 of the Employment Contract, the Employee will return all documents, correspondence, other information carriers, copies thereof, and other data or information of Employer.  All items will be returned in clean and good condition to the Employer by the Termination Date.
​
18.      Non-Competition and Restrictive Clauses.  Clause 10 (confidentiality obligation) of the Employment Contract will continue to apply according to its terms after the Termination Date. Clause 13 (non-compete and business relationship clause) and Clause 16 (penalty clause) of the Employment Contract are replaced with this Section 18.
​
18.1   Permitted Activities.  The provisions of Clauses 18.2 through 18.4 shall not apply in the following limited circumstances provided in this Section 18.1 (the “Permitted Activities”), provided that Employee is otherwise in full compliance with the terms of Clauses 18 and 19:
​
18.1.1 Employee shall be allowed to act as an Operating Partner at Forbion, including conceptualizing, searching, sourcing, evaluating and working on deal flow for Forbion Fund IV, Forbion Fund V, Forbion Growth Opportunities Fund I, and BioGeneration Ventures IV and any other new Forbion or BGV Fund.
​
18.1.2 Employee shall be allowed to act in the capacity as an employee, director, advisor or consultant at Oxitope Pharma B.V. on the research and development of antibodies for oxidized phospholipids for inflammation, including for the development of a gene therapy format for certain Oxitope antibodies and dyslipidemia-related complications such as NASH and vascular dementias.
​
18.1.3 Employee shall be allowed to act in the capacity as an employee, director, advisor or consultant at Dyne Therapeutics (https://www.dyne-tx.com/) on the research and development of anti-sense and gene-skipping technologies for Duchenne, DMD and other muscle diseases based on antibody-DNA conjugates.
​
 18.1.4 Employee shall be allowed to serve on the Scientific Advisory Boards of Forbion’s portfolio companies Engene Inc. (advising on the research and development of gene therapies for diseases of the digestive system, lungs and bladder) and Hookipa Pharma Inc. (advising on the research and development of arena virus gene vector-based vaccines and treatments of immunotherapeutics, targeting infectious diseases and cancers).
​
18.1.5 In addition to the activities described in Clauses 18.1.1 through 18.1.4, Employee shall be allowed to act in the capacity of an employee, director, advisor or consultant for any company engaged in the research, development and other business activities in the Additional Permitted Fields (as defined below), including the research and development of gene therapies in such fields (more specifically including but not limited to such gene therapies targeting the central nervous system, liver or using Adeno Associated Virus Serotype 5 (AAV5)), provided that Employee provides advance written notice to Employer of any work in such Additional Permitted Fields (consisting of a notice of the name of the company, the date such work is to commence and the scope of the field the Employee will be working in). Additional Permitted 
​

Fields means the fields of: dyslipidemia (excluding ANGPTL3); oxidized phospholipids; and any additional targets or indications that may be added pursuant to the following provisions of this Section 18.1.5. Employee shall be allowed to add additional targets or indications to the list of Additional Permitted Fields upon written notice (including email to legalnotices@uniqure.com) to Employer and Employer’s written acknowledgement within two weeks of receipt of such notice that such additional target or indication was not an area being evaluated, researched or developed by Employer or its affiliates: (i) in the case of a program or project involving AAV5, during the period from Employee’s date of hire through the date of the written notice of such additional target or indication; and (ii) in the case of all other programs or projects, during the period from Employee’s date of hire through the Termination Date.  In the event the acknowledgement in the foregoing sense cannot be given, the Employer shall provide the Employee with sufficient documentation in order for the Employee to be able to properly verify that such additional target or indication was indeed an area being evaluated, researched or developed by Employer or its affiliates during the applicable period.  (For clarification, the requirement that Employee provide notice to Employer of work in Additional Permitted Fields shall only apply during the Non-Competition Period, which expires August 31, 2021.)
​
18.1.6 Notwithstanding the above, Employee acknowledges that he shall not at any time be allowed to be engaged in any activity involving the use of proprietary technologies of Employer or its affiliates as evidenced in writing (by  electronic or other documents), including, without limitation, miQURE technology, Synpromics promoters, uniQure’s Dual Bac technology, uniQure’s insect cell rep patents and technology, and uniQure’s proprietary technology built on AAV5 technology.
​
18.2   Non-Competition. Except as provided in Clause 18.1, during the period beginning on execution of this Agreement and extending through August 31, 2021 (the “Non-Competition Period), without the prior written consent of the Employer (which will not be unreasonably withheld), the Employee shall not be engaged or involved or have any share in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties (including, without limitation, in any role (paid or unpaid) as an employee, director, advisor, or consultant), in any enterprise competing with that of the Employer and/or the Employer’s affiliates (including, the fields of gene therapies targeting the central nervous system, gene therapies targeting the liver, and gene therapies using Adeno-Associated Virus Serotype 5 (aka AAV5)), nor act, in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, as an intermediary in relation to such activities.
​
18.3   Except as provided in Clause 18.1, for the Non-Competition Period, without the prior written consent of the Employer (which will not be unreasonably withheld), the Employee shall not perform or have performed professional services in connection with any product or research or development or commercialization that competes with products, or research or development or commercialization of Employer (“Employer’s Activities”), directly or indirectly, (including, in the fields of gene therapies targeting the central nervous system, gene therapies targeting the liver, and gene therapies using Adeno-Associated Virus Serotype 5 (aka AAV5)) whether on his own behalf or for third parties, provided the Employer’s Activities have been started prior to the Termination Date.
​

​
18.4   RESERVED.
​
18.5   Non-Solicitation of uniQure Employees. Both during the term of the Agreement and during the Non-Competition Period, without the prior written consent of the Employer (which will not be unreasonably withheld), the Employee shall refrain,  from becoming engaged or involved in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, in actively enticing away, taking (or causing to have taken) into employment, nor make use of, in any manner whatsoever, directly or indirectly, whether on his own behalf or for third parties, the work of employees or persons who in a period beginning one year prior to the Termination Date and extending through the Non-Competition Period are or have been in the employment of the Employer and/or the Employer’s affiliates (“uniQure Employees”, each a “uniQure Employee”).  Employee shall make any company or other third party he works for as an employee, consultant, or advisor aware of his obligations pursuant to this Clause 18.  Notwithstanding the provisions of Section 18.1, it shall not be a “Permitted Activity” for Employee to work as (or continue to work as) an employee, consultant or advisor for any company or other third party that, during the Non-Competition Period, takes into employment, or makes use of, in any manner whatsoever, directly or indirectly, the work of a uniQure Employee.  In the case of a large pharmaceutical company having multiple divisions or a university of higher education, the hiring of a uniQure Employee for a project or division unrelated to the services being performed by Employee will not affect the status of any otherwise “Permitted Activity”.
​
18.6   Employee acknowledges and agrees to adhere to this clause as the Employer has a serious business interest in binding the Employee to the non-competition and business relationship clause, due to the fact that (i) within the organization of the Employer competition-sensitive information as well as confidential information related to the Employer, such as but not limited to products, or research or development or commercialization of Employer (“Sensitive Business Information”) are available and (ii) in the position of Executive Vice President, Research and Product Development the Employee has had access to this Sensitive Business Information and may have continued access to such Sensitive Business Information and/or has maintained contacts with partners, suppliers, competitors etc. Given the aforesaid considerations (i) and (ii) in this clause, combined with the education and capacities of the Employee, the Employer has a well-founded fear that its business interest will be harmed substantially if the Employee performs competing activities as set forth in Clause 18 during the Non-Competition Period.
​
18.7   Penalty Clause.  In the event the Employee acts in violation of any of the obligations under the articles 18 through 19 of this Agreement or Article 10 of the Employment Agreement (Confidentiality), the Employee shall (upon written objective substantiation of such violation), contrary to section 7:650 paragraphs 3, 4 and 5 Dutch Civil Code, without notice of default being required, forfeit to the Employer for each such violation, a penalty in the maximum amount of EUR 10.000,00 comprising of as well as a penalty of EUR 1.000,00 for each day such violation has taken place and continues. Alternatively, the Employer will be entitled to claim full damages.  Employee acknowledges that certain economic benefits beyond the severance provisions of his Employment Agreement have been provided in this Agreement (including, the acceleration of certain equity grants), and the value of such additional benefits would be included as part of any claim for full damages.
​

​
19.      Employee agrees, to the extent permitted by law, that he will not, at any time after the Effective Date hereof, make any negative announcements, remarks or comments, orally or in writing that reasonably could be construed to be derogatory or disparaging to the Employer or its affiliates (collectively, the “Company”) or any of shareholders, officers, directors, employees, attorneys or agents, of the Company, or which reasonably could be anticipated to be damaging or injurious to the Company’s reputation or good will or to the reputation or good will of any person associated with the Company.  Notwithstanding the above, your non-disparagement obligation shall not prohibit you from testifying truthfully in any legal proceeding or as otherwise required by law.
​
20.      As of the Termination Date, Employee releases and forever discharges the Employer and its affiliates and each of their directors, officers and employees from each and every claim in law or equity that Employee may have had, or may have, that has arisen directly or indirectly out of, or that relates directly or indirectly to, any circumstance, agreement, activity, action, omission, event or matter occurring or existing prior to the Termination Date.
​
21.      The Parties will release an internal and external notification announcing the termination of the Employment Contract of the Employee.  The external announcement is targeted to be released within one week of the Effective Date but will be determined between Parties.  The content of the external communication will be coordinated between Employee and Employer’s Investor Relations department. The internal announcement will be made shortly prior to the external announcement on a date and time to be determined by Employer. Prior to the internal announcement, Employee will not discuss his (potential) departure with the staff. The (content of the) internal announcement will be coordinated between Employee and the Employer’s Human Resources department.  Notwithstanding the forgoing, Employer may make any public disclosure, including disclosure of the Agreement, that is reasonably required by law.
​
22.      If any of the Employee’s social media profiles state that he works for the Employer, no later than on the Termination Date the Employee must ensure that those references are updated to reflect the actual situation, either by removing the reference or by stating the date on which his or her employment ended.
​
23.      The Parties will observe strict confidentiality in respect of third parties regarding both the formation and the substance of this Agreement unless the law orders or reasonably requires either Party to disclose this Agreement or parts thereof.
​
24.      The Parties waive their rights to rescind this Agreement. In the event that a court holds any provision of this Agreement to be void or otherwise non-binding, the remaining provisions of this Agreement will remain in full force and effect.
​
25.      With the exception of the obligations arising from this Agreement, the Employee and the Employer, including its affiliated legal entities, employees and directors, grant each other full and final discharge from liability regarding all claims arising from the Employment Contract, its termination or the CAO (where applicable) or for whatever other reason.
​
​

26.      By signing this Agreement, the Employee expressly declares that (a) he has a proper and full understanding of the substance and consequences of this Agreement, (b) he agrees to the substance and consequences of this Agreement, (c) he has been given the opportunity to seek assistance or advice from a legal advisor, and (d) he has not concealed any facts and/or circumstances of which he should reasonably be aware that they could have affected this Agreement.
​
27.      Since the Employee resigns and this Agreement is solely meant to lay down the consequences of this resignation for the period until the Termination Date and the period thereafter as well as the fact that the Employee intends to start in a new position with another employer, the Parties are of the opinion that this Agreement does not qualify as an early retirement scheme (RVU).
​
28.      This Agreement is a settlement agreement within the meaning of Section 900 of Book 7 of the Dutch Civil Code. Therefore, Sections 900 up to and including 906 of Book 7 of the Dutch Civil Code apply to this Agreement.
​
29.      This Agreement is governed by Dutch law. The Dutch courts have jurisdiction to hear any disputes ensuing from it.
​
Agreed and signed in duplicate,
​
	Signed for approval:
	​
	Signed for approval:

	​
	​
	​

	​
	​
	​

	/s/J. L. Burggraaf
	​
	/s/ S.J.H. van Deventer

	On behalf of uniQure biopharma B.V.
	​
	Employee

	J.L. Burggraaf
	​
	S.J.H. van Deventer

	​
	​
	​

	Date: August 25, 2020
	​
	Date: August 25, 2020

	City: Amsterdam
	​
	City: Amsterdam

​
Signed for Release of Claims on the Termination Date:
​
	​

	​

	​
	​

	/s/ S.J.H. van Deventer
	​

	Employee
	​

	Date: September 14, 2020
	​

	City: Amsterdam
	​

​Exhibit 10.2
​
August 25, 2020
Robert Gut
	​

	​

	Re:
	Separation from Employment

​
Dear Robert,
​
As we have discussed, the purpose of this letter agreement (“Agreement”) is to set forth our mutual understanding and agreement concerning the terms and conditions of your separation from employment with uniQure, Inc. (the “Company”), which generally are described in the Employment Agreement between you and the Company dated March 1, 2020 (the “Employment Agreement”).  In consideration of the mutual promises set forth below, we have agreed as follows:
​
1.     Separation from Employment.
​
a.   As of the thirtieth (30th) day following the commencement of the employment of the Company’s President, Research & Development (your “Separation Date”), you hereby resign, and your separation from employment shall be effective as of the Separation Date (your “Separation Date”).  You also resign your position as an executive director of uniQure N.V. effective as of your Separation Date.  You relinquish as of the Separation Date any and all positions that you have held with the Company, and you will not be considered an employee or director of the Company or any of its affiliates for any purpose after that date.  If the employment of the Company’s President, Research & Development has not commenced by October 31, 2020, this Agreement shall be null and void.
​
b.   During the period from the execution of this Agreement through the Separation Date, you shall continue in your current role with your current duties, but you may be assigned additional or different duties by the Chief Executive Officer or his designee to assist with and effect a transition of the organization.
​
c.   The Parties expect that, following your resignation as an executive director of uniQure N.V., the Board of Directors of uniQure N.V. (the “Board”) will nominate you for appointment as a non-executive director of uniQure N.V. at an extraordinary meeting of shareholders, but the Parties acknowledge that such a nomination is solely at the discretion of the Board and is not a promise, obligation, or inducement of this Agreement.
​
d.   You and the Company will develop an internal and external communication plan that is reasonable in the circumstances and mutually agreeable to the Parties.
​
​
​

Robert Gut
Separation Agreement
Page 2

​
2.   Final Compensation.  Regardless of whether you accept this Agreement, on your Separation Date, the Company shall provide you with your Accrued Benefits, as that term is defined in the Employment Agreement.  Specifically, the Company shall provide you with final payment of base salary due for time worked through the Separation Date as well as payment for any accrued but unused vacation time.  You agree that such payment represents all compensation to which you are entitled in connection with your employment.  Any additional requests by you for reimbursement of business expenses must be submitted for payment using the Company’s standard expense reimbursement system no later than the Separation Date.
​
3.   Separation Payment.  Subject to: (i) the Company’s receipt of this Agreement signed by you; (ii) your full acceptance of the terms of, and full performance under, this Agreement (including, without limitation, your acceptance of the general release of legal claims contained in Paragraph 9 below (the "General Release")); (iii) your satisfactory performance of the responsibilities and duties of your position with the Company up through your Separation Date, and (iv) the expiration of the seven (7) day revocation period contained in Paragraph 11 below (the "Revocation Period") without revocation):
​
a.   the Company agrees to pay you with a lump sum severance payment equal to Six Hundred Ninteen Thousand Five Hundred Forty-Nine dollars ($619,549) (i.e., 140% of your annual base salary of base annual salary of Four Hundred Forty-Two Thousand Five Hundred Thirty-Five dollars ($442,535)) less all applicable federal, state and local taxes and other withholdings.
​
b.   the Company further agrees to pay you a Pro-rata Bonus calculated as the product of the formula B x (D/365), where B represents Forty percent (40%) of your annual base salary of Four Hundred Forty-Two Thousand Five Hundred Thirty-Five dollars ($442,535), and D represents the number of days from January 1, 2020 through the Separation Date.
​
c.   The lump sum severance payment of Section 3(a) and the Pro-rata Bonus of Section 3(b) are collectively referred to as the (the "Separation Payment"). The Separation Payment will be made to you no later than thirty (30) days following the date you sign and deliver this Agreement to the Company and after the Revocation Period has expired without any notice of revocation by you.
​
d.   Provided that you and your eligible dependents, if any, are participating in the Company’s group health, dental and vision plans on the termination date and elect on a timely basis to continue that participation in some or all of the offered plans through the federal law commonly known as “COBRA,” the Company will pay or reimburse you for your full COBRA premiums (i.e., employer and employee portion) until the earlier to occur of: (a) twelve (12) months from the Separation Date, (b) the date you become eligible to enroll in the health, dental and/or vision plans of another employer, (c) the date you (and/or your eligible dependents, as applicable) are no longer eligible for COBRA coverage, or (d) the Company in good 
​

Robert Gut
Separation Agreement
Page 3

faith determines that payments under this paragraph would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of 2010, as amended, and any guidance or regulations promulgated thereunder (collectively, “PPACA”). You agree to notify the Company promptly if you become eligible to enroll in the plans of another employer or if you or any of your dependents cease to be eligible to continue participation in the Company’s plans through COBRA.
​
4.   Tax Provision.  In connection with the Separation Payment provided to you pursuant to this Agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such Separation Payment under applicable law.  The Company does not guarantee any particular tax effect for any of the payments or other consideration set forth in this Agreement, and you shall be solely responsible and liable for the satisfaction of all taxes, penalties and interest that may be imposed on you or for your account in connection with the Agreement (including any taxes, penalties and interest under IRC Section 409A), and the Company shall not have any obligation to indemnify or otherwise hold you (or any beneficiary) harmless from any or all of such taxes, penalties or interest. You acknowledge that you are not relying upon advice or representation of the Company with respect to the tax treatment of any of the separation benefits set forth in this Agreement.
​
5.   Health Insurance Continuation.  Regardless of whether you accept this Agreement, you will remain on the Company’s insured health plan at the level(s) you are currently enrolled through October 31, 2020.  Notice of your rights and obligations concerning continuation of coverage shall be sent to you under separate cover in accordance with applicable law.
​
6.   Status of Employee Benefits and Stock Options.  Except as otherwise expressly provided in Section 5 of this Agreement, your participation in all employee benefit plans of the Company shall end as of your Separation Date in accordance with the terms of those plans. Information will be provided on terminating participation in all plans, including either maintaining your existing 401k account, or rolling it over to another provider.  The Company confirms that you will have vested Stock Options, Performance Share Units (“PSUs”), and Restricted Share Units (“RSU’s”) as of your Separation Date pursuant to the terms of your grants.  Stock Options may be exercised pursuant to the terms and conditions of your Share Option Agreements and the Company’s Amended and Restated 2014 Share Incentive Plan.  You will not be eligible to participate in the Company Employee Stock Purchase Plan (“ESPP”) for any current or future offering period.  For any any such offering period, the Company will refund any payroll contributions that you may have made pursuant to the ESPP, and no stock will be purchased on your behalf.  This Agreement does not grant or promise to grant any equity, and, except where expressly provided, does not modify the terms of any prior grant of equity or modify the terms of any agreement signed pursuant to a grant of equity.  The terms of the grants of equity and agreements signed pursuant to grants of equity shall control in case of conflict with this Agreement.
​
​

Robert Gut
Separation Agreement
Page 4

​
7.   Confidentiality.  As a material inducement to the Company to enter into this Agreement, you agree to keep any non-public aspects of this Agreement (including any negotiations or discussions related hereto)(“Agreement-Related Information”), in complete confidence.  Except as you may be required by local, state or federal law or regulation or by compulsory process of law, and provided that in case of such requirement you shall immediately, unless precluded by law, notify the Company of such requirement in writing, you agree that neither you nor any person acting by, through, under, or in concert with you will, at any time, disclose Agreement-Related Information, except for disclosures: (i) to an attorney of your choice who may be advising you in connection with this Agreement; (ii) to your accountant or tax preparer; or (iii) to your immediate family, provided that all such persons to whom you disclose such information are first advised by you prior to such disclosure of the confidential nature of the information and your obligations under this Agreement, and further provided that the subsequent disclosure by any such persons of the amount of this settlement or the terms of this Agreement will be treated as if you had made such disclosure; and (iv) and, in any event, you shall at no time disclose Agreement-Related Information to any current or former employee of the Company.
​
8.   Non-Disparagement/Cooperation. You agree, to the extent permitted by law, that you will not, at any time after the date hereof, make any remarks or comments, orally or in writing, to any customer, potential customer, partner, supplier, employee, shareholder, potential investor, or any other person, which or who have, or could reasonably be anticipated to have, business dealings with the Company, which remarks or comments reasonably could be construed to be derogatory or disparaging to the Company or any of its shareholders, officers, directors, employees, attorneys or agents, or which reasonably could be anticipated to be damaging or injurious to the Company’s reputation or good will or to the reputation or good will of any person associated with the Company.  Notwithstanding the above, your non-disparagement obligation shall not prohibit you from testifying truthfully in any legal proceeding.
​
9.   General Release.
​
(a)  You hereby irrevocably and unconditionally release, acquit and forever discharge the Company, its parent entities and corporations, subsidiaries (whether wholly or partially owned), divisions, affiliates, predecessors, successors and assigns, and its and  their respective current and former partners, owners, agents, directors, officers, fiduciaries, employees, supervisors, managers, representatives, attorneys, insurers and reinsurers, and all persons and entities acting by, through, under or in concert with the Company or any of the aforementioned entities or individuals, in their personal and professional capacities (collectively the "Releasees"), from any and all claims, demands, and causes of action of whatever kind or nature, including without limitation, all claims, demands, and causes of action arising from your employment or separation from employment with the Company, that you or your
​

Robert Gut
Separation Agreement
Page 5

heirs, executors, administrators, successors or assigns have, may have, or have at any time had, prior to the date you sign this Agreement against the Releasees, or any of them, whether arising under tort, contract, or other law and whether arising under state, federal, or other law including, but not limited to, Title VII of the Civil Rights Act of 1964 and as amended by the Civil Rights Act of 1991, 42 U.S.C. §§ 2000e, et seq.; the Americans with Disabilities Act, 42 U.S.C. §§ 12101, et seq, as amended; the Age Discrimination in Employment Act (including, without limitation, the Older Workers' Benefit Protection Act), 29 U.S.C. §§ 623, et seq.; the National Labor Relations Act, as amended, 29 U.S.C., § 151 et seq.; the Occupational Safety and Health Act, as amended; the Immigration Reform Control Act, as amended; § 503 of the Rehabilitation Act of 1973, 29 U.S.C. §§ 701, et seq.; the Civil Rights Act of 1866, 42 U.S.C. § 1981; except as otherwise provided herein the Consolidated Omnibus Budget Reconciliation Act of 1985, 42 U.S.C. § 1395(c); Executive Order 11246; the Employee Retirement  Income Security Act, 29 U.S.C. §§ 1132 (a)(l)(B), et seq.; the federal Workers Adjustment and Retraining Notification Act, 29 U.S.C. §§ 2101 et seq.; Sarbanes­ Oxley Act of 2002, Public Law 107-204, including whistleblowing claims under 18 U.S.C. §§ 1514A and 1513(e); the Family and Medical Leave Act, 29 U.S.C. §§ 2601 et seq; all claims arising out of the claims under the MA Fair Employment Practices Act, M.G.L. c. 151B, the MA Wage and Hour laws, M.G.L. c. 149, et. al., M.G.L. c. 93, and all other claims and rights under any other federal, state, and local statutory and common law, including but not limited to public policy, contract and tort and any and all claims arising from any injuries or damages suffered by you, for attorney's fees, costs, non­ payment, or any other claim or damage you could assert against the Company and/or the Releasees. For the avoidance of doubt, this release includes any claims under the under the Massachusetts Wage Act and State Overtime Laws, including without limitation G.L. c. 149 § 148, 150 et seq. and G.L. c. 151 § lA et seq.  You promise not to sue any of the Releasees on any of these released claims.
​
(b)  You represent and warrant to the Company that no portion of any claim, demand, cause of action, or other matter released by you herein, nor any portion of any recovery or settlement to which you might be entitled from any Releasee, has been assigned or transferred to any other person or entity, either directly or by way of subrogation or operation of law.
​
(c)  You acknowledge that you have been granted by the Company all requested paid and/or unpaid leave to which you may have been entitled. You represent that you are not aware of any facts that would support a claim by you against any of the Releasees for any violation of the Family and Medical Leave Act. You further acknowledge that you have been properly paid for all time worked and are unaware of any facts that would support a claim by you against any of the Releasees for any claim of unpaid wages or overtime or any other violation of the Fair Labor Standards Act or state wage and hour law.
​
​

Robert Gut
Separation Agreement
Page 6

Notwithstanding the above, this Release does not include and shall not preclude (a) any rights to any vested benefits or vested rights under employee benefit plans under the Employee Retirement Income Security Act (29 U.S.C. § 1001 et seq.), as amended; (b) any claims arising from a breach of this Agreement or rights to enforce this Agreement; (c) any action or proceeding against the Company for acts, incidents, occurrences, or inactions occurring after the execution of this Agreement and (d) any rights to indemnification that exist as of the Separation Date by the Company and/or the Company’s insurers from any claims against you by any third party involving your employment with the Company.
​
10. Protected Rights.  You understand that nothing contained in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). You further understand that this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. You understand that you waive and release any personal entitlement to reinstatement, back pay, or any other types of damages, or injunctive relief, in connection with any actions taken by you on your behalf on your complaint or charge.  You understand that by executing the General Release, you are forever releasing and waiving any and all claims against the Releasees.
​
11. Acknowledgments. You acknowledge and agree that you understand the meaning of this Agreement and that you freely and voluntarily enter into it and the General Release.  You agree that no fact, evidence, event, or transaction, whether known or unknown, shall affect in any manner the final and unconditional nature of this Agreements and the General Release.  Pursuant to the Older Workers Benefit Protection Act, you acknowledge that you have been advised:
(i)  that you have twenty-one (21) days to consider this Agreement and General Release;
​
(ii)  any modifications to this Agreement, whether material or immaterial, will not restart the twenty-one (21) day consideration period;
​
(iii)  to consult with an attorney prior to executing this Agreement and General Release;
​
(iv)  by signing this Agreement and General Release you will give up important legal rights, including the right to sue the Company;
​
(v)  this Agreement and General Release does not release any 
​

Robert Gut
Separation Agreement
Page 7

claims that arise after the execution of this Agreement and General Release; and
​
(vi)  for a period of seven (7) days after executing this Agreement and General Release, you may revoke this Agreement and General Release by providing written notice of said revocation to me at the address of the Company set forth above, and this Agreement and General Release shall not become effective or enforceable until said seven-day period has expired without your revocation.
​
In the event that you execute this Agreement and General Release prior to the expiration of the twenty-one (21) day period during which you may consider it, you represent and acknowledge that you have done so voluntarily and of your own free will without any coercion or compulsion of any nature by the Company or anyone associated with the Company.
​
12. Acknowledgement of Confidentiality, Developments and Restrictive Covenants Agreement.  You acknowledge that you are bound by the Company’s Confidentiality, Developments, and Restrictive Covenants Agreement, which copy is attached here as Exhibit 1 (the “Confidentiality Agreement”), including, without limitation, the provisions regarding confidentiality, disclosure and assignment of inventions, non-competition, non-solicitation, disclosure of certain provisions to future employers, tolling of post-employment obligations, and return of Company property.  You further acknowledge that, pursuant to Section 8 of the Confidentiality Agreement, the Confidentiality Agreement shall survive your separation from the Company.  (In case of a conflict between this Agreement and the Confidentiality Agreement, this Agreement shall control).  You also acknowledge and represent that  you have returned all property of the Company as required in Section 19 of the Confidentiality Agreement, including, without limitation, all documents, devices, equipment, keys, security passes, credit cards, hardware, data, databases, source code, object code, and data or computer programming code stored on an optical or electronic medium, and any copies thereof, relating to uniQure’s business and affairs, including any Confidential Information or any reference thereto, and you further represent that you are in compliance with Section 19 of the Confidentiality Agreement.  Notwithstanding the foregoing, nothing in Exhibit 1 or set forth herein is intended to or shall interfere with your rights under the Defend Trade Secrets Act of 2016 which provides, in part, that “[a]n individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
​
13. Consulting.  You agree that you will provide consulting services to the Company as 
​

Robert Gut
Separation Agreement
Page 8

requested on an as-needed basis for the period beginning simultaneously with your separation from the Company and through the one-year anniversary of the Separation Date (the “Consulting Period”).  You will provide consulting services consistent with your current position with the Company to assist in the transition of the clinical operations organization.  Such services will be directed by the Chief Executive Officer or his delegee.  The services shall be limited to no more than eight hours per week.  You will be reimbursed at a rate of $500 per hour for the actual time spent providing such consulting services, to be invoiced monthly.  If you are appointed as a non-executive director of uniQure N.V. by vote at an Annual or Extraordinary Meeting of Shareholders, the consultancy pursuant to this Section shall terminate immediately and simultaneously upon such appointment.  The consultancy may be terminated only as provided in this Agreement, or by mutual agreement of the parties.  For clarity, the parties intend that your grants of equity pursuant to the Company’s Amended and Restated 2014 Share Incentive Plan will continue to vest during the Consulting Period on the terms of such grants.
​
14. Governing Law and Interpretation. This Agreement shall be construed in accordance with the laws of the Commonwealth of Massachusetts without regard to choice or conflict of law principles. The language of all parts of this Agreement shall be construed as a whole, according to its fair meaning, and not strictly for or against either party.
​
15. Interpretation of Agreement.  This Agreement sets forth the entire agreement between the parties pertaining to the subject matter hereof.  Notwithstanding the foregoing, this Agreement does not abrogate, limit, or otherwise impair any of the Company’s rights or any of your post-employment obligations under the Confidentiality, Developments and Restrictive Covenants Agreement. Likewise, this Agreement does not supersede or impair any of the terms or condition of any Performance Share Unit Agreement, Share Option Agreement, or the Company’s Amended and Restated 2014 Share Incentive Plan.
​
16. No Reliance.  You represent and acknowledge that, in executing this Agreement, you do not rely and have not relied upon any representation or statement outside this written agreement made by any of the Releasees or by any of the Releasees’ agents, representatives or attorneys with regard to the subject matter, basis or effect of this Agreement.
​
17. Waiver.  Failure to insist on compliance with any term, covenant or condition contained in this Agreement shall not be deemed a waiver of that term, covenant or condition, nor shall any waiver or relinquishment of any right or power contained in this Agreement at any one time or more times be deemed a waiver or relinquishment of any right or power at any other time or times.
​
18. Severability and Modification.  Should any term or provision of this Agreement be declared illegal, invalid or unenforceable by any court of competent jurisdiction and if such provision cannot be modified to be enforceable, such provision shall immediately become null and void, leaving the remainder of this Agreement in full force and effect.
​

Robert Gut
Separation Agreement
Page 9

Provided however, if your General Release is found invalid, illegal, and/or unenforceable, you agree to enter into a full and General Release with the Company that is not invalid, illegal and/or unenforceable without payment of additional consideration.
​
19. Amendment.  This Agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.  This Agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.
20. Representation.  You represent that the Company has advised you, and you have had the opportunity, to thoroughly discuss all aspects of this Agreement with legal counsel, that you have read and understand the provisions herein, and that you are voluntarily entering into this Agreement.
	 ​

	​

	​

	​
	uniQure, Inc.

	​
	         /s/ Matthew Kapusta

	
	​
	By:
	Matthew Kapusta
	​

	​
	​
	Chief Executive Officer

​
AGREED TO AND EXECUTED THIS _24th DAY OF _August___________________ 2020.
​
/s/ Robert Gut___________
Robert Gut
​
(Acknowledgement below to be signed on Separation Date.)
​
AKNOWLEDGED AND AGREED, INCLUDING, WITHOUT LIMITATION, THE GENERAL RELEASE OF CLAIMS, AS OF OCTOBER _14_, 2020.
​
/s/ Robert Gut___________
Robert Gut
​
​

Robert Gut
Separation Agreement
Page 10

​
EXHIBIT 1
​
Confidentiality, Developments, and Restrictive Covenants Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]